- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07281638
Bedside Bike Early Mobilization Program for Inpatients (BB-STEP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background and Rationale:
Immobility during hospitalization is a widespread and often preventable cause of disability, particularly among older adults and patients recovering from critical illness. Research demonstrates that very modest activity confers significant benefits: walking just 275 steps per day reduces 30-day readmissions by 10% in older inpatients, and a single 20-minute cycling session on weekdays shortens length of stay and improves functional recovery in ventilated ICU patients. However, most patients remain largely immobile despite being physiologically capable of low-intensity exercise.
The Bedside Bike addresses key barriers to inpatient mobility by eliminating the need to transfer out of bed (reducing fall risk), requiring less than 1 minute of staff setup time (addressing staffing constraints), providing adjustable resistance for progressive exercise, and allowing patients to exercise independently without navigating hallways with IV lines and catheters. The device is FDA-cleared (Class I, product code ION, 21 CFR §890.5370) and has been tested with healthcare providers and healthy volunteers without safety concerns.
Study Design and Implementation:
This is a prospective, single-arm quality improvement implementation study conducted across three Indiana University Health hospital units: IU Methodist Post-ICU step-down unit, IU Bloomington ortho/neuro and medical/surgical units, and IU North medical/surgical unit. The study uses a pragmatic design embedded within routine clinical care, with contemporaneous historical unit-level metrics from 2025 serving as comparison benchmarks.
Device Setup and Operation:
After informed consent, the Bedside Bike is installed at the bedside and patients receive training on its use. The device clamps securely to the bed frame with pedals positioned approximately 10 cm above the mattress. Patients can adjust resistance via a dial and exercise at their own pace, targeting at least one 15-minute session daily. A quick-release lever allows the device to be disengaged in under 2 seconds if needed for patient transfers or clinical procedures.
The Bedside Bike includes a Bluetooth-enabled telemetry module that automatically records exercise metrics including duration, revolutions per minute, and resistance level. Data is encrypted and uploaded nightly to a secure REDCap database at Indiana University. Between patients, the device is cleaned with standard hospital disinfectant, and Clinical Engineering performs weekly quality assurance checks.
Integration with Standard Care:
Patients continue all standard medical care without restrictions. Physical therapy, occupational therapy, and progressive ambulation programs proceed as usual. The Bedside Bike is designed to augment-not replace-skilled therapy sessions. There are no restrictions on pain medications, sleep aids, or nutritional support. Cycling is temporarily paused during hemodialysis or when telemetry alarms require clinical attention.
Data Safety Monitoring:
The Principal Investigator leads weekly data safety monitoring huddles to review enrollment progress, device utilization patterns, and adverse events. Any unanticipated serious adverse event triggers immediate IRB notification within 48 hours. The study protocol includes automatic pause criteria: enrollment halts if any device-related serious adverse event occurs or if feasibility drops below 40% for two consecutive weeks, pending comprehensive safety review.
Duration and Follow-up:
The enrollment period spans 3 months (February through April 2026) with approximately 16 patients enrolled monthly across all sites. Each participant is followed through hospital discharge plus 60 days post-discharge. The final 60-day follow-up is completed by the end of June 2026, with database lock and analysis extending through September 2026.
Statistical Design:
With N=80 participants, the study provides 90% power (α=0.05, two-tailed, assuming SD of 2 days) to detect a clinically meaningful 0.2-day reduction in length of stay compared to historical unit averages. This sample size accounts for potential dropouts and incomplete data. Missing data under 5% will be handled using multiple imputation (m=5 iterations); higher rates of missingness will default to complete-case analysis.
This pragmatic feasibility study will provide critical data on device utilization, safety profile, and preliminary effectiveness signals to inform the design of larger randomized controlled trials and guide clinical implementation strategies for in-bed cycling technology across diverse inpatient populations.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Theresa Joyce
- Phone Number: 317-278-1882
- Email: tajoyce@iu.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years or older
- Admitted to participating hospital unit within 24 hours or less
- Expected hospital stay of at least 3 days
- Able to follow one-step commands
- Anti-gravity leg strength
- Informed consent obtained from patient or legally authorized representative
Exclusion Criteria:
- Hemodynamic instability requiring vasopressor support with systolic blood pressure <90 mmHg
- Requiring fraction of inspired oxygen (FiO₂) >0.6 or positive end-expiratory pressure (PEEP) >8 cm H₂O
- Uncontrolled cardiac arrhythmia
- Open lower extremity wounds within the pedal arc area
- Lower limb fracture requiring traction or immobilization
- Active deep vein thrombosis (DVT) without therapeutic anticoagulation
- Body mass index (BMI) >45 kg/m² (exceeds device reach limit)
- Current pregnancy
- Concurrent enrollment in another interventional clinical trial that would conflict with study procedures or outcomes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Group (receiving Bedside Bike + Usual Care)
All enrolled participants receive the Bedside Bike device plus standard hospital care.
Installed within 24 hours of admission, patients are trained on device operation and safety.
Setup takes <1 minute.
Patients use the device daily throughout hospitalization, targeting ≥15 minutes per session.
Exercise is self-paced with adjustable resistance via patient-controlled dial.
Recumbent (in-bed) cycling allows unsupervised, patient-initiated use without staff presence.
Average duration is 5-7 days (enrollment to discharge).
Participants continue all standard care including physical/occupational therapy, ambulation, medications, and nutrition.
|
The Bedside Bike is a Class I medical device (21 CFR §890.5370,
product code ION) featuring a magnetic resistance mechanism powering arm and leg pedal systems with a universal clamp for standard hospital bed frames.
Key safety features include smooth surfaces without sharp edges, immediate stop mechanism with no momentum carry-over, cushioned pedals supporting single-pedal operation for hemiparesis, self-retracting tether cable preventing entanglement, battery-powered operation eliminating tripping hazards, nearly silent operation, lightweight construction, and soft-start/soft-stop resistance adjustment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device Utilization Feasibility
Time Frame: First 5 hospital days (or until discharge if sooner)
|
Percentage of enrolled participants who achieve at least 75 cumulative minutes of Bedside Bike use during their first 5 hospital days.
Success criterion: ≥80% of participants meet this threshold.
|
First 5 hospital days (or until discharge if sooner)
|
|
Incidence of Device-Related Adverse Events
Time Frame: From enrollment through hospital discharge, approximately 5-7 days on average
|
Rate of device-related adverse events (AEs) and serious adverse events (SAEs).
Safety success criteria: zero device-related SAEs and ≤5% rate of minor device-related AEs.
Device-related events are defined as any adverse outcome directly attributable to the Bedside Bike device itself or its use.
|
From enrollment through hospital discharge, approximately 5-7 days on average
|
|
Hospital Length of Stay
Time Frame: From hospital admission to discharge, approximately 5-7 days on average
|
Duration of index hospitalization in days, compared to 2025 unit-specific median length of stay.
Target: reduction of ≥0.2 days versus historical benchmark.
|
From hospital admission to discharge, approximately 5-7 days on average
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in AM-PAC 6-Clicks Mobility Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in Activity Measure for Post-Acute Care (AM-PAC) "6 Clicks" Basic Mobility Inpatient Short Form score from baseline to discharge.
Target: improvement of ≥2 points.
Score range 6-24, with higher scores indicating better mobility function.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in AM-PAC 6-Clicks Activities of Daily Living Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in Activity Measure for Post-Acute Care (AM-PAC) "6 Clicks" Activities of Daily Living (ADL) Inpatient Short Form score from baseline to discharge.
Score range 6-24, with higher scores indicating better ADL function.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Discharge Disposition to Home
Time Frame: At hospital discharge, approximately 5-7 days after admission
|
Percentage of participants discharged directly home (versus inpatient rehabilitation facility, skilled nursing facility, long-term acute care hospital, or death).
Target: increase of ≥7% compared to 2025 unit-specific historical rate.
|
At hospital discharge, approximately 5-7 days after admission
|
|
Incidence of Hospital-Acquired Weakness
Time Frame: At hospital discharge, approximately 5-7 days after admission
|
Percentage of participants with hospital-acquired weakness defined as Medical Research Council (MRC) sum score <48 at discharge.
MRC sum score assesses strength in 12 muscle groups bilaterally (range 0-60), with scores <48 indicating clinically significant weakness.
Target incidence: <30%.
|
At hospital discharge, approximately 5-7 days after admission
|
|
New Institutionalization at 60 Days Post-Discharge
Time Frame: 60 days post-hospital discharge
|
Percentage of participants requiring new placement in skilled nursing facility, long-term care facility, or inpatient rehabilitation facility at 60 days post-discharge (among those discharged home initially).
|
60 days post-hospital discharge
|
|
Change in One-Minute Sit-to-Stand Repetitions
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in number of sit-to-stand repetitions completed in one minute from baseline to discharge.
This test measures lower extremity strength and functional capacity.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Six-Minute Walk Test Distance
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in distance walked in six minutes from baseline to discharge, measured in meters.
This test assesses cardiorespiratory fitness and functional exercise capacity.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in EQ-5D Quality of Life Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in EQ-5D (EuroQol 5-Dimension) health-related quality of life score from baseline to discharge.
The EQ-5D assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Hospital Anxiety and Depression Scale (HADS)
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in HADS total score from baseline to discharge.
HADS consists of anxiety and depression subscales (each 0-21, total 0-42), with higher scores indicating greater symptom severity.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Berg Balance Scale Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in Berg Balance Scale score from baseline to discharge.
Scale ranges 0-56, with higher scores indicating better balance.
Scores <45 indicate higher fall risk.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Timed Up and Go Test Duration
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in time (seconds) required to stand from a chair, walk 3 meters, turn around, walk back, and sit down from baseline to discharge.
Shorter times indicate better functional mobility.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Quadriceps Isometric Strength
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in quadriceps muscle strength measured via handheld dynamometry from baseline to discharge, measured in kilograms of force or Newtons.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Johns Hopkins Highest Level of Mobility (JH-HLM) Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in JH-HLM score from baseline to discharge.
Scale ranges 1-8, with higher scores indicating greater mobility independence (1=lying in bed to 8=ambulating >250 feet).
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Estimated VO2 Max
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in estimated maximal oxygen consumption (VO2 max) from baseline to discharge, measured in mL/kg/min.
VO2 max indicates cardiorespiratory fitness.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Braden Skin Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in Braden Scale for Predicting Pressure Sore Risk from baseline to discharge.
Scale ranges 6-23, with lower scores indicating higher risk for pressure ulcer development.
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
Change in Morse Fall Scale Score
Time Frame: Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
Change in Morse Fall Scale score from baseline to discharge.
Scale ranges 0-125, with higher scores indicating greater fall risk (0-24=low risk, 25-50=moderate risk, ≥51=high risk).
|
Baseline (within 24 hours of admission) to discharge (approximately 5-7 days)
|
|
60-Day Hospital Readmission Rate
Time Frame: 60 days post-hospital discharge
|
Percentage of participants readmitted to any hospital within 60 days of discharge from index hospitalization, assessed via medical record review.
|
60 days post-hospital discharge
|
|
Incidence of Falls Within 60 Days Post-Discharge
Time Frame: 60 days post-hospital discharge
|
Number and percentage of participants experiencing one or more falls after hospital discharge, occurring in any setting (home, post-acute care facility, or community), assessed via medical record review and telephone follow-up.
|
60 days post-hospital discharge
|
|
60-Day All-Cause Mortality
Time Frame: 60 days post-hospital discharge
|
All-cause mortality within 60 days of hospital discharge, assessed via medical record review and telephone follow-up.
|
60 days post-hospital discharge
|
|
Living Setting at 60 Days Post-Discharge
Time Frame: 60 days post-hospital discharge
|
Participant's living arrangement at 60 days post-discharge, categorized as: home (independent), home (with assistance), skilled nursing facility, long-term care facility, inpatient rehabilitation, other, or deceased.
|
60 days post-hospital discharge
|
|
Total Healthcare Costs Through 60 Days
Time Frame: From hospital admission through 60 days post-discharge (approximately 65-75 days total)
|
Total direct healthcare costs including index hospitalization and all healthcare utilization within 60 days post-discharge, obtained from de-identified aggregated claims data.
Costs measured in US dollars.
|
From hospital admission through 60 days post-discharge (approximately 65-75 days total)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chris Gales, DPT, Indiana University
- Principal Investigator: Babar Khan, MD, Indiana University
Publications and helpful links
General Publications
- Burtin C, Clerckx B, Robbeets C, Ferdinande P, Langer D, Troosters T, Hermans G, Decramer M, Gosselink R. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med. 2009 Sep;37(9):2499-505. doi: 10.1097/CCM.0b013e3181a38937.
- Binder EF, Schechtman KB, Ehsani AA, Steger-May K, Brown M, Sinacore DR, Yarasheski KE, Holloszy JO. Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. J Am Geriatr Soc. 2002 Dec;50(12):1921-8. doi: 10.1046/j.1532-5415.2002.50601.x.
- Hastings SN, Sloane R, Morey MC, Pavon JM, Hoenig H. Assisted early mobility for hospitalized older veterans: preliminary data from the STRIDE program. J Am Geriatr Soc. 2014 Nov;62(11):2180-4. doi: 10.1111/jgs.13095. Epub 2014 Oct 30.
- Krumholz HM. Post-hospital syndrome--an acquired, transient condition of generalized risk. N Engl J Med. 2013 Jan 10;368(2):100-2. doi: 10.1056/NEJMp1212324. No abstract available.
- Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003 Oct 8;290(14):1868-74. doi: 10.1001/jama.290.14.1868.
- Brown CJ, Friedkin RJ, Inouye SK. Prevalence and outcomes of low mobility in hospitalized older patients. J Am Geriatr Soc. 2004 Aug;52(8):1263-70. doi: 10.1111/j.1532-5415.2004.52354.x.
- Daniels R, van Rossum E, de Witte L, Kempen GI, van den Heuvel W. Interventions to prevent disability in frail community-dwelling elderly: a systematic review. BMC Health Serv Res. 2008 Dec 30;8:278. doi: 10.1186/1472-6963-8-278.
- Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ 3rd. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002 Jun 10;162(11):1245-8. doi: 10.1001/archinte.162.11.1245.
- Brown CJ, Redden DT, Flood KL, Allman RM. The underrecognized epidemic of low mobility during hospitalization of older adults. J Am Geriatr Soc. 2009 Sep;57(9):1660-5. doi: 10.1111/j.1532-5415.2009.02393.x. Epub 2009 Aug 4.
- Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009 Apr 2;360(14):1418-28. doi: 10.1056/NEJMsa0803563.
- Regenbogen SE, Cain-Nielsen AH, Syrjamaki JD, Chen LM, Norton EC. Spending On Postacute Care After Hospitalization In Commercial Insurance And Medicare Around Age Sixty-Five. Health Aff (Millwood). 2019 Sep;38(9):1505-1513. doi: 10.1377/hlthaff.2018.05445.
- Pasina L, Cortesi L, Tiraboschi M, Nobili A, Lanzo G, Tettamanti M, Franchi C, Mannucci PM, Ghidoni S, Assolari A, Brucato A; REPOSI Investigators. Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study. Arch Gerontol Geriatr. 2018 Jan;74:169-173. doi: 10.1016/j.archger.2017.10.016.
- Cao J, Wang T, Li Z, Liu G, Liu Y, Zhu C, Jiao J, Li J, Li F, Liu H, Liu H, Song B, Jin J, Liu Y, Wen X, Cheng S, Wan X, Wu X. Factors associated with death in bedridden patients in China: A longitudinal study. PLoS One. 2020 Jan 29;15(1):e0228423. doi: 10.1371/journal.pone.0228423. eCollection 2020.
- Yang SY, Kim ES, Jeon G, Choi KY, Kim JK. Enhanced adhesion of osteoblastic cells on polystyrene films by independent control of surface topography and wettability. Mater Sci Eng C Mater Biol Appl. 2013 Apr 1;33(3):1689-95. doi: 10.1016/j.msec.2012.12.081. Epub 2013 Jan 2.
- English KL, Paddon-Jones D. Protecting muscle mass and function in older adults during bed rest. Curr Opin Clin Nutr Metab Care. 2010 Jan;13(1):34-9. doi: 10.1097/MCO.0b013e328333aa66.
- Drummond MJ, Dickinson JM, Fry CS, Walker DK, Gundermann DM, Reidy PT, Timmerman KL, Markofski MM, Paddon-Jones D, Rasmussen BB, Volpi E. Bed rest impairs skeletal muscle amino acid transporter expression, mTORC1 signaling, and protein synthesis in response to essential amino acids in older adults. Am J Physiol Endocrinol Metab. 2012 May 15;302(9):E1113-22. doi: 10.1152/ajpendo.00603.2011. Epub 2012 Feb 14.
- Chizhikov VV, Millen KJ. Control of roof plate development and signaling by Lmx1b in the caudal vertebrate CNS. J Neurosci. 2004 Jun 23;24(25):5694-703. doi: 10.1523/JNEUROSCI.0758-04.2004.
- Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, Mohr DN, O'Fallon WM. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001 Nov;76(11):1102-10. doi: 10.4065/76.11.1102.
- Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008 Feb 2;371(9610):387-94. doi: 10.1016/S0140-6736(08)60202-0.
- Agmon M, Zisberg A, Gil E, Rand D, Gur-Yaish N, Azriel M. Association Between 900 Steps a Day and Functional Decline in Older Hospitalized Patients. JAMA Intern Med. 2017 Feb 1;177(2):272-274. doi: 10.1001/jamainternmed.2016.7266. No abstract available.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Mental Disorders
- Pathologic Processes
- Disease Attributes
- Confusion
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Embolism and Thrombosis
- Thrombosis
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Delirium
- Venous Thrombosis
- Mobility Limitation
- Iatrogenic Disease
Other Study ID Numbers
- 28224
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delirium
-
Alexandria UniversityCompletedClozapine Poisoning | Hypoactive Delirium | Tricyclic Antidepressant Poisoning | Anticholinergic Delirium | Antipsychotic Toxicity | CNS Depression | Procyclidine Induced DeliriumEgypt
-
Efficacy Care R&D LtdHadassah Medical OrganizationUnknownDelirium | Delirium, Cause Unknown | Delirium of Mixed Origin | Delirium Confusional State | Delirium Drug-InducedIsrael
-
Imperial College Healthcare NHS TrustRecruitingCardiac Surgery | Intensive Care Unit Delirium | Post Operative DeliriumUnited Kingdom
-
Duke UniversityNot yet recruitingDelirium Confusional State | Hyperactive Delirium | Delirium in the Intensive Care Unit | Agitated DeliriumUnited States
-
Sengkang General HospitalRecruitingDelirium and Post-operative Cognitive Dysfunction (POCD) | Delirium, Postoperative | Delirium - PostoperativeSingapore
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicCompletedDelirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional StateNorway
-
Universitat de LleidaHospital d'IgualadaNot yet recruitingDelirium in Old Age | Delirium Treatment | Delirium Confusional StateSpain
-
Wonkwang University HospitalCompleted
-
Menoufia UniversityCompleted
-
Universidad de SantanderUnknownDelirium of Mixed Origin | Hypoactive Delirium | Hyperactive DeliriumColombia
Clinical Trials on Bedside Bike
-
Cara J. HamannEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedAdolescent | Attitudes | Education | Self Efficacy | Behavior | Safety | Knowledge | Practice | BicyclingUnited States
-
Mersin UniversityCompleted
-
Humanitas Clinical and Research CenterRecruitingCritical Illness | Mechanical Ventilation Complication | Weaning Failure | Diastolic Heart Failure | Diastolic DysfunctionItaly
-
University Hospital, GhentUniversity GhentCompletedPatient Participation | Nursing | Bedside Shift ReportBelgium
-
The Hospital for Sick ChildrenOntario Ministry of Health and Long Term CareCompletedClinically Deteriorating Paediatric PatientsCanada
-
Hamilton Health Sciences CorporationCompletedCritical Illness | Critical Illness Myopathy | Thoracic Surgery | Cardiac Disease | Critical Illness PolyneuropathyCanada
-
University Hospital, BonnRecruiting
-
IRCCS Eugenio MedeaPolitecnico di Milano; Villa Beretta Rehabilitation Center; National Research...Completed
-
Taipei Veterans General Hospital, TaiwanCompletedIntensive Care Unit PatientsTaiwan
-
Peking University First HospitalCompleted